Pain management using nanotechnology approaches

Beiranvand, Siavash; Sorori, Mohamad Masud

doi:10.1080/21691401.2018.1553885

Cited by 18 publications

(14 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The specificity of antidepressants can be amended by conjugating a ligand covalently to the polymeric nanoparticles [ 23 ]. As a drug carrier, it displays sustained drug release, biodegradability, prolonged duration, ability to deliver peptides, proteins, and genes through the oral route of administration, and high stability during storage [ 23 , 73 ]. Moreover, polymeric nanoparticles can cross the BBB via receptor-mediated endocytosis [ 74 ].…”

Section: Nanocarriers Employed As Therapeutic Delivery Platforms Of Antidepressantsmentioning

confidence: 99%

“…As discussed above, nanotechnology offers a remarkable potential to improve the therapeutic effect of antidepressants. Nevertheless, nano-drug delivery systems have been reported in several studies to cause neurotoxicity [ 73 ]. For example, in vitro studies and clinical trials indicated that nanoparticles exhibit minor or major toxicity effects depending on the degree of toxicity of the biopolymers [ 73 ].…”

Section: Toxicity Of Nano-based Antidepressantsmentioning

confidence: 99%

“…Nevertheless, nano-drug delivery systems have been reported in several studies to cause neurotoxicity [ 73 ]. For example, in vitro studies and clinical trials indicated that nanoparticles exhibit minor or major toxicity effects depending on the degree of toxicity of the biopolymers [ 73 ]. In an independent study, the degradation of other biopolymers such as PLGA could also induce cell damage due to the generation of an acidic medium which was dependent on the amount of polymer administered [ 35 , 91 ].…”

Section: Toxicity Of Nano-based Antidepressantsmentioning

confidence: 99%

See 2 more Smart Citations

Advances in Nano-Enabled Platforms for the Treatment of Depression

et al. 2021

View full text Add to dashboard Cite

Nanotechnology has aided in the advancement of drug delivery for the treatment of several neurological disorders including depression. Depression is a relatively common mental disorder which is characterized by a severe imbalance of neurotransmitters. Several current therapeutic regimens against depression display drawbacks which include low bioavailability, delayed therapeutic outcome, undesirable side effects and drug toxicity due to high doses. The blood–brain barrier limits the entry of the drugs into the brain matrix, resulting in low bioavailability and tissue damage due to drug accumulation. Due to their size and physico-chemical properties, nanotechnological drug delivery systems present a promising strategy to enhance the delivery of nanomedicines into the brain matrix, thereby improving bioavailability and limiting toxicity. Furthermore, ligand-complexed nanocarriers can improve drug specificity and antidepressant efficacy and reduce drug toxicity. Biopolymers and nanocarriers can also be employed to enhance controlled drug release and reduce the hepatic first-pass effect, hence reducing the dosing frequency. This manuscript reviews recent advances in different biopolymers, such as polysaccharides and other nanocarriers, for targeted antidepressant drug delivery to the brain. It probes nano-based strategies that can be employed to enhance the therapeutic efficacy of antidepressants through the oral, intranasal, and parenteral routes of administration.

show abstract

Section: Nanocarriers Employed As Therapeutic Delivery Platforms Of Antidepressantsmentioning

confidence: 99%

Section: Toxicity Of Nano-based Antidepressantsmentioning

confidence: 99%

Section: Toxicity Of Nano-based Antidepressantsmentioning

confidence: 99%

See 1 more Smart Citation

Advances in Nano-Enabled Platforms for the Treatment of Depression

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Instead, a search for “nanotechnology in pain” produced about 7975 publications from 1996. According to a review article from 2018 by Beiranvand and Sorori [137], the proper treatment of pain is still a major medical challenge; therefore, different approaches using various nano-formulated materials have been employed in the last decade. According to Moradkhani et al [138], analgesic drug delivery nanosystems have been applied in pain therapy due to their remarkable properties: enhanced drug delivery profile, increased drug action and bioavailability, targeted/sustained or prolonged drug release profile, stability in biological fluids, nontoxicity, carried drug protection up to the target cell population, and reduced side effects of the incorporated analgesic drugs [139].…”

Section: Pain and Cf Managementmentioning

confidence: 99%

Current Practices and Potential Nanotechnology Perspectives for Pain Related to Cystic Fibrosis

Trandafir

Leon

Frăsinariu

et al. 2019

JCM

View full text Add to dashboard Cite

Pain is a complex, multidimensional process that negatively affects physical and mental functioning, clinical outcomes, quality of life, and productivity for cystic fibrosis (CF) patients. CF is an inherited multi-system disease that requires a complete approach in order to evaluate, monitor and treat patients. The landscape in CF care has changed significantly, with currently more adult patients than children worldwide. Despite the great advances in supportive care and in our understanding regarding its pathophysiology, there are still numerous aspects of CF pain that are not fully explained. This review aims to provide a critical overview of CF pain research that focuses on pain assessment, prevalence, characteristics, clinical association and the impact of pain in children and adults, along with innovative nanotechnology perspectives for CF management. Specifically, the paper evaluates the pain symptoms associated with CF and examines the relationship between pain symptoms and disease severity. The particularities of gastrointestinal, abdominal, musculoskeletal, pulmonary and chest pain, as well as pain associated with medical procedures are investigated in patients with CF. Disease-related pain is common for patients with CF, suggesting that pain assessment should be a routine part of their clinical care. A summary of the use of nanotechnology in CF and CF-related pain is also given. Further research is clearly needed to better understand the sources of pain and how to improve patients’ quality of life.

show abstract

“…Acute postoperative pain is one of the common complaints [ 1 , 2 ]. Its treatment is one of the important health-related issues and a number of guidelines have been recommended to treat the pain [ 3 , 4 ]. After surgery, pain assessment is considered as a fifth vital sign [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

The effect of preoperative sublingual buprenorphine on postoperative pain after lumbar discectomy: A randomized controlled trial

Kiabi

Emadi

Shafizad

et al. 2021

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

Background Lumbar discectomy is one of the most common surgical procedures performed to manage pain caused by the protrusion of an intervertebral disc. Postoperative pain management can be challenging and might lead to increased intake of opioids. Objective : The aim of this study was to determine the effect of preoperative sublingual buprenorphine on severity of pain after lumbar disc surgery and postoperative intake of morphine. Methods This Randomized clinical trial study was performed on 78 patients who were selected for lumbar discectomy surgery. Patients were randomly divided into two groups of 39 patients, each. Patients in the buprenorphine and placebo group received 2 mg buprenorphine sublingual, and placebo 1 h before surgery. Severity of pain, nausea, vomiting and pruritus and intake of opioids in the two groups were evaluated and recorded 1, 6, 12 and 24 h after surgery. Data were analyzed using SPSSv21. Results There was a significant difference in pain score in buprenorphine group at 1, 6, 12, and compared with placebo (P < 0.005). In the control group, the use of analgesics was more than the buprenorphine group. In the first hours after surgery (1–6 h), the incidence of nausea in the buprenorphine group was significantly lower than of the control group (P < 0.05). However, at 12 and 24 h, this difference was not observed, p > 0.05. There was no significant difference in incidence of side effects (nausea, vomiting, pruritus) in the two groups (P > 0.05). Conclusion Sublingual buprenorphine in postoperative pain management is an effective and low dose drug. Due to its simpler administration, it is recommended to relief postoperative pain after lumbar disc surgery.

show abstract

Pain management using nanotechnology approaches

Cited by 18 publications

References 79 publications

Advances in Nano-Enabled Platforms for the Treatment of Depression

Advances in Nano-Enabled Platforms for the Treatment of Depression

Current Practices and Potential Nanotechnology Perspectives for Pain Related to Cystic Fibrosis

The effect of preoperative sublingual buprenorphine on postoperative pain after lumbar discectomy: A randomized controlled trial

Contact Info

Product

Resources

About